ACE — Ascelia Pharma AB Share Price
0.000.00%
Last trade - 00:00- SEK401.72m
- SEK380.92m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.4 | ||
| Price to Tang. Book | 23.28 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -148.87% | ||
| Return on Equity | -85.65% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ascelia Pharma AB is a Sweden-based pharmaceutical company focused on the development of novel oncology therapies. The Company identifies, acquires and develops differentiated, underappreciated and derisked investigational medicinal drug candidates to make them available to cancer patients. The Company's pipeline includes Mangoral and Oncoral. Mangoral is a medical imaging drug candidate for use in liver Magnetic Resonance Imaging (MRI) for detection and localization of liver metastases in patients with impaired kidneys, which has completed phase II of clinical studies. Oncoral is a tablet formulation of chemotherapeutic agent irinotecan under clinical development for the treatment of gastric cancer. It has completed phase I of clinical studies.
Directors
- Peter Benson CHM (66)
- Magnus Corfitzen CEO (45)
- Kristian Borbos CFO (42)
- Julie Waras Brogren DSL
- Carl Bjartmar OTH (57)
- Hans Maier DRC (65)
- Niels Mengel DRC (73)
- Rene Spogard DRC (66)
- Bo Hansen IND (63)
- Helena Wennerstrom IND (55)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 4th, 1999
- Public Since
- March 13th, 2019
- No. of Employees
- 13
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 34,871,177
- Address
- Hyllie Boulevard 34, MALMO, 215 32
- Web
- https://www.ascelia.com/
- Phone
- +46 462863760
- Contact
- Mikael Widell
- Auditors
- Ohrlings PricewaterhouseCoopers AB
Upcoming Events for ACE
Ascelia Pharma AB Annual Shareholders Meeting
Q1 2024 Ascelia Pharma AB Earnings Release
Q2 2024 Ascelia Pharma AB Earnings Release
Similar to ACE
2cureX AB
OMX Nordic Exchange Stockholm
Abliva AB
OMX Nordic Exchange Stockholm
Acousort AB
OMX Nordic Exchange Stockholm
Active Biotech AB publ
OMX Nordic Exchange Stockholm
AddLife AB
OMX Nordic Exchange Stockholm
FAQ
What is the Ascelia Pharma AB share price?
As of Today at 19:02 UTC, shares in Ascelia Pharma AB are trading at SEK11.52. This share price information is delayed by 15 minutes.
How has the Ascelia Pharma AB share price performed this year?
Shares in Ascelia Pharma AB last closed at SEK11.52 and the price had moved by -20% over the past 365 days. In terms of relative price strength the Ascelia Pharma AB share price has underperformed the FTSE Global All Cap Index by -26.21% over the past year.
What are the analyst and broker recommendations for Ascelia Pharma AB?
The overall consensus recommendation for Ascelia Pharma AB is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Ascelia Pharma AB dividend yield?
Ascelia Pharma AB does not currently pay a dividend.
Does Ascelia Pharma AB pay a dividend?
Ascelia Pharma AB does not currently pay a dividend.
When does Ascelia Pharma AB next pay dividends?
Ascelia Pharma AB does not currently pay a dividend.
How do I buy Ascelia Pharma AB shares?
To buy shares in Ascelia Pharma AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Ascelia Pharma AB?
As of the previous close price of SEK11.52, shares in Ascelia Pharma AB had a market capitalisation of SEK401.72m.
Where are Ascelia Pharma AB shares listed?
Here are the trading details for Ascelia Pharma AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: ACE
What kind of share is Ascelia Pharma AB?
Based on an overall assessment of its quality, value and momentum Ascelia Pharma AB is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Ascelia Pharma AB share price forecast for 2024?
The analyst consensus target price for shares in Ascelia Pharma AB is SEK12.00. That is 4.17% above the last closing price of SEK11.52.
Analysts covering Ascelia Pharma AB currently have a consensus Earnings Per Share (EPS) forecast of -SEK1.29 for the next financial year.
What is the trend in the Ascelia Pharma AB share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ascelia Pharma AB. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +188.66%.
As of the last closing price of SEK11.52, shares in Ascelia Pharma AB were trading +71% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Ascelia Pharma AB PE Ratio?
The Ascelia Pharma AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK11.52.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Ascelia Pharma AB?
Ascelia Pharma AB's management team is headed by:
- Peter Benson - CHM
- Magnus Corfitzen - CEO
- Kristian Borbos - CFO
- Julie Waras Brogren - DSL
- Carl Bjartmar - OTH
- Hans Maier - DRC
- Niels Mengel - DRC
- Rene Spogard - DRC
- Bo Hansen - IND
- Helena Wennerstrom - IND